Perrigo launches generic Axiron

DUBLIN — Perrigo on Wednesday announced the introduction of its generic of Axiron (testosterone, 30 mg/1.5 ml) topical solution. The drug is indicated for replacement therapy in males with an endogenous testosterone deficiency or absence.

“This is our third new product launch in the last two weeks,” Perrigo EVP and president Rx Pharmaceuticals John Wesolowski said. “These new product launches illustrate our continued focus on developing and bringing to market important treatments in prescription extended topical therapeutic categories. The Rx team remains committed to investing in complex topical products and to launching more than five new products by the end of 2017.”

The drug had annual market sales of $248 million for the 12 months ended April 2017.